1) For the influenza A (H1N1) component of the 2022-2023 influenza virus vaccines in the U.S., does the committee recommend:
   - an A/Victoria/2570/2019 (H1N1) pdm09-like virus (Egg-based Vaccines)
   - an A/Wisconsin/588/2019 (H1N1) pdm09-like virus (Cell- or Recombinant-based Vaccines)

2) For the influenza A (H3N2) component of the 2022-2023 influenza virus vaccine in the U.S., does the committee recommend:
   - an A/Darwin/9/2021 (H3N2)-like virus (Egg-based Vaccines)
   - an A/Darwin/6/2021 (H3N2)-like virus (Cell- or Recombinant-based Vaccines)

3) For the influenza B component of the 2022-2023 trivalent and quadrivalent influenza virus vaccines in the U.S., does the committee recommend inclusion of a B/Austria/1359417/2021-like virus (B/Victoria lineage)

4) For quadrivalent 2022-2023 influenza vaccines in the U.S., does the committee recommend inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2nd influenza B strain in the vaccine